Biocon and Pfizer terminate commercialization agreement

March 15, 2012 10:34 AM

Biocon 300 Biocon and Pfizer terminate commercialization agreement

Biocon and Pfizer announced this week, the conclusion of their alliance to commercialize Biocon’s biosimilar versions of Insulin and Insulin analog products.

The companies have agreed that due to the individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently.

Biocon and Pfizer are committed to ensuring continuity of patient care and will work together to effect a seamless transition. As of March 12, 2012, all rights licensed to Pfizer will revert to Biocon, and all insulin distributed under the brand name Univia and Glarvia will be commercially available from Biocon Ltd. only, and will be exclusively manufactured, supplied, marketed and supported by Biocon.

“Biocon remains committed to delivering its Biosimilar Insulins portfolio to global markets in its endeavour to make a difference to diabetic patients across emerging and developed economies. Biocon will continue to work with its existing partners in several markets and will pursue a commercial strategy on its own and through new alliances in other markets.” said Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon Limited.

“Pfizer continues to be dedicated to developing a broad portfolio of biosimilars medicines, including monoclonal antibodies and recombinant proteins products, both internally and through collaborations” said Diem Nguyen, General Manager – Biosimilars, Pfizer, “In addition, we will continue to be active in our own research and business development efforts for diabetes, which represents a huge unmet medical need, and we remain committed to seeking new solutions to help physicians and patients.”


Source: Biocon press release

Related posts:

  1. A biosimilar manufacturer: Biocon

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.
We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!

Latest Posts on Biosimilar News

  • Events Upcoming Events

    8th Monoclonal Antibodies 2012

    VisionGain is organizing the 8th Monoclonal Antibodies Conference in London, UK between 22-24 May,  2012.  If you attend the conference, you will be able to: • Identify key advances in antibody technology: nanobodies, conjugates, scFvs, and BiTEs • Discover new therapeutic applications in oncology, autoimmune disorders and ophthalmology • Gain insight into future for biosimilar mAbs and how they might affect market share • Investigate the application of phage display libraries and screening techniques to identify new target antigens. • [...]

    Read more →
  • News/Headlines

    Synthon concluded Phase I clinical trial for trastuzumab

    Synthon announced yesterday that it has successfully concluded a phase I clinical trial for trastuzumab, a biosimilar to Herceptin, for treatment of breast cancer and gastric cancer. The company will now initiate a phase III clinical trial for trastuzumab, bringing an affordable alternative for treatment of breast and gastric cancer closer to the market. All in vitro and in vivo studies conducted so far showed biosimilar behavior of Synthon’s trastuzumab in comparison with the reference product, Herceptin. The outcome of the phase I clinical [...]

    Read more →
  • News/Headlines

    Mabthera&Herceptin prices get lower in India

    According to Wall Street Journal, Roche will be cutting the price of two expensive cancer drugs in India, in an effort to gain market share and avoid competition from biosimilars.  Roche will be giving new names to the drugs in India and the company hopes to avoid losing pricing power elsewhere, though it isn’t clear the company will succeed on that score. Lately, Roche signed an agreement with Emcure of India to locally pack these well-known cancer drugs in India. After [...]

    Read more →
  • Research/Analysis

    A biosimilar manufacturer: Pfenex

    Headquartered in San Diego, California, Pfenex Inc., is a leading biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars. According to company’s website, Pfenex is utilizing Pf?nex Expression Technology to build a portfolio of biosimilar molecules. Pfenex does not want to repeat the innovator’s protein expression and bioprocess strategy that may have been developed more than 20 years ago. The company applies its parallel processing, toolbox approach to strain development to [...]

    Read more →
  • News/Headlines
© Copyright 2012 — Biosimilar News. All Rights Reserved Powered by Wordpress